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Abstract
The authors present an analysis of current research and their own data on the
link between endothelial dysfunction (ED) and the severity of depression in
middle-aged patients with cerebral microangiopathy. Levels of peripheral inflam-
matory and endothelial dysfunction markers were measured using the enzyme-
linked immunosorbent assay (ELISA). The results of the comparative and correla-
tion analyses showed a statistically significant correlation between the severity of
depression and increased levels of inflammatory, as well as endothelial dysfunction
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1. Introduction
Depression and cardiovascular diseases (CVD) are the leading problems of
modern healthcare [1]. The global prevalence of depressive disorders ranges from
4.4 to 20%. Аbout 350 million people suffer from depression [2, 3].
The World Health Organization (WHO) considers depression and atherosclero-
sis as the main causes of disability in CVD and predicts that by 2030, depression will
be the leading one. The fact that a depressive disorder is more common in women
and the elderly people (in whom CVD is often underestimated) determines the
need for effective preventive measures in these risk groups [4, 5].
Themultiple factors contributing to the strong association between depression and
atherosclerosis are not well studied. Authors discuss various mechanisms of linkage
between these diseases [6–12], i.e., the activation of neuroendocrine system [5].
Frequently, depression is considered an unfavorable prognostic factor for the
CVD development [6–8]. Unhealthy lifestyle (physical inactivity, smoking), as well
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as inflammation and metabolic syndrome, has been proposed to explain the rela-
tionship between depression and the development of atherosclerosis [9, 10, 12, 13].
In patients with depression, elevated levels of such markers of systemic inflam-
mation as pro-inflammatory cytokines (tumor necrosis factor alpha (TNF-α),
interleukin-6 (IL-6)), C-reactive protein (CRP), as well as reduced levels of inter-
leukin-1 (IL-1) and interleukin-8 (IL-8) [14–17], lead to hyperactivation of the
hypothalamic-pituitary-adrenal axis [18]. Also intestinal inflammation causes
remote effect on the brain and depression. Unbalanced gut microbiota shifts tryp-
tophan metabolism toward kynurenine pathway affecting gamma-aminobutyric
acid (GABA), dopamine, and serotonin levels [19, 20]. Studies have shown that
stimulation of the vagus nerve modulates the inflammatory response and relieves
the depression symptoms [21, 22].
Many studies focus on the activation of inflammatory processes as a common
pathogenetic pathway between CVD, cerebrovascular disorders, and depression. In
this respect, there are two aspects of the role of pro-inflammatory mechanisms: the
first reveals the causal relationship between depression and inflammation and/or
endothelial dysfunction (ED); the second shows the connection between inflam-
mation, ED, and atherosclerosis [5]. ED and/or elevated levels of peripheral markers
of inflammation are found in atherosclerosis and cardiovascular events [23].
Patients at high risk of acute coronary syndrome can be identified based on the
elevated levels of inflammatory markers [24]. These markers are associated with
atherosclerosis and activation of the immune system. The immune system compo-
nents can indirectly influence the progression of atherosclerotic vascular lesions.
Risk factors for CVD, which at the same time predispose to atherosclerosis, cause
dysfunction of the vascular endothelium. The vascular endothelium, as a regulator
of vascular homeostasis, is involved in different processes, such as keeping a balance
between vasodilatation and vasoconstriction, inhibition and stimulation of smooth
muscle cell proliferation and migration, thrombus formation, and fibrinolysis [25].
When imbalance occurs, ED develops, causing excessive vascular permeability,
platelet aggregation, leukocyte adhesion, and production of cytokines. A failure in
synthesis or a violation of the activity of nitric oxide (NO) (which is manifested by
insufficient vasodilatation) also is considered as a potential mechanism by which
endothelial dysfunction leads to atherosclerosis. The low systemic levels of NO have
been postulated to be responsible for the increased risk of cardiovascular events
observed in subjects with depression, as NO produces vasodilatation [26].
Among other cardiovascular risk factors, obesity increases morbidity and mor-
tality from CVD. The relationship between depression and obesity is complex and
includes behavioral, biological, and pathological associations [27]. The mechanisms
leading to the development of obesity affect the vascular system and especially the
endothelium function, mainly due to the pathological role of TNF-α in the genera-
tion of reactive oxygen species and reducing the availability of NO [28].
Significantly more research is needed to further study the multiple associations
between inflammation, markers of ED, and depression in patients with CVD [29].
Therefore, we have performed our own study aimed at identifying the relationship
between the levels of peripheral inflammatory markers and markers of ED with the
level of depression in patients with cerebral microangiopathy associated with arte-
rial hypertension and cerebral atherosclerosis.
2. Materials and methods, results, discussion
The study included middle-aged (44–60 years old) outpatients of both sexes,
with cerebral microangiopathy. The diagnosis was based on (1) the presence of a
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vascular disease (arterial hypertension and/or cerebral atherosclerosis) and focal
neurological symptoms in combination with cerebral symptoms (headache, dizzi-
ness, noise in the head, memory loss, etc.), (2) ultrasonic signs of cerebrovascular
atherosclerosis according to duplex scanning of the main arteries of the head, and
(3) signs of morphological changes in the brain according to neuroimaging data
(subcortical and periventricular leucoaraiosis and/or focal changes of gray and
white matter in the form of postischemic cysts and/or lacunary strokes and/or
diffuse atrophic changes in the form of ventricular dilatation or subarachnoid
spaces). Also all patients had depression (≥8 points on the Hospital Anxiety and
Depression Scale (HADS)). Study participants were capable of communicating with
the researcher, understanding and signing the informed consent form.
All patients received Divaza for 3 months. Divaza is a drug with endothelial
protective as well as nootropic (neuroprotective, neurotrophic) activity and good
safety profile [30–54].
Combination drug Divaza was developed based on previously discovered
pharmacological effects of its active pharmaceutical ingredients—release-active anti-
bodies to S100 (RAF of Abs to S100) and release-active antibodies to endothelial NO
synthase (RAF of Abs to eNOS) (including their different technological versions). The
important feature of RA forms of a substance is the ability to exert modifying effect on the
original substance or its target [Symmetry, 2018]. Since this activity is released during
technological processing of the original substance, it has been termed as the released
activity and the produced drug as the released-active drug.
Preclinical studies have shown that Divaza successfully combines properties of the
monocomponents [see Appendix 1]. The overall therapeutic effect results in an enhanced
ability of experimental animals to remember and reproduce the developed skills as well as
overcome artificially induced anxiety and depression. Furthermore, therapeutic effect of
Divaza on functional activity of endothelium has been confirmed by normalizing such
integrative indicator of the physiological status as blood pressure: RAF of Abs to eNOS
exerted hypotensive effect in animals with arterial hypertension and, at the same time,
did not alter parameters of system hemodynamics in normotensive condition. Impor-
tantly, RAF of Abs to eNOS given to animals along with nitroglycerin, an exogenous
NO-donor, resulted neither in a drug-drug interaction nor in excessive vasodilation (the
drug did not enhance the nitroglycerin effect in normotensive animals).
Noteworthy, Divaza, while exerting a normalizing psychotropic effect, did not cause
sedation and/or muscle relaxation (unpublished data).
RAF of Abs to S100, RAF of Abs to eNOS, and combination drug Divaza did
not exert any toxic effect as assessed by evaluation of single- and repeat-dose
(chronic) toxicity, genotoxicity, reproductive and developmental toxicity,
local tolerance, allergenic properties and immunotoxicity even when administered
at doses more than 100 times exceeding the recommended human daily doses
[31, 32].
During the study, patients were allowed to take concomitant drugs for
correcting the main risk factors for CVD development (antihypertensive drugs,
diuretics, antiplatelet drugs, anticoagulants, statins, and antidiabetic drugs).
An assessment of the dynamics of clinical and laboratory parameters was
performed at baseline and after 3 months of therapy. Clinical examination of
patients included collecting and analyzing complaints, anamnesis, anthropometric
measurements of body weight and height to calculate body mass index (BMI), and
thorough neurological examination, including neuropsychological testing and
emotional status assessment using HADS.
Serum levels of peripheral markers of endothelial inflammation (CRP, monocyte
chemoattractant protein-1 (MCP-1)) as well as biomarkers of ED (endothelin-1,
eNOS, vascular endothelial growth factor (VEGF), S100B protein, von Willebrand
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factor, fibrinogen) were determined by ELISA. The amount of circulating desqua-
mated endothelial cells (CECs) was detected according to J. Hladovec with modifi-
cations.
ELISA reference values of biomarkers were CRP up to 1 mg/l, MCP-1 0.228–
0.475 ng/ml, endothelin-1 0.3–0.5 ng/ml, eNOS y < 450 units VEGF 101–409 pg/
ml, S100B protein 29–56.5 μg/l, CECs 2–4 cells/100 μl, von Willebrand factor < 4
cu, and fibrinogen 2–4 g/l.
The study included a total of 262 patients between 44 and 60 years of age (mean
age 54.2  7) with cerebral microangiopathy and depression. Among patients there
were 110 (42.1%) men (mean age 50.8  6.3) and 152 (57.9%) women (mean age
57.4  8.1). One hundred ninety-eight (75.6%) patients had grade 1 arterial hyper-
tension, 64 (24.4%) had grade 2 arterial hypertension, 152 (58%) had type 2 diabe-
tes mellitus, and 169 (64.5%) had obesity (BMI > 30 kg/m2). The severity of
depression on the HADS hospital scale was 12.84  5.67 points.
The sociodemographic and clinical characteristics of patients are presented in
Table 1.
The initial patient sample (n = 262) was divided into two groups: a group with
clinically significant depression (≥11 points on the HADS scale) (n = 146) and a
group with subclinically significant depression (8–10 points on the HADS scale)
(n = 116). At the time of inclusion in the study, no statistically significant differ-
ences between groups by sociodemographic characteristics were identified.
A comparative analysis revealed that in the group of patients with clinically
significant depression (n = 146), the CRP level was 6.11 mg/l, which was
statistically different from the group of patients with subclinical depression
(n = 116) where CRP was 2.03 mg/L (p < 0.05). The level of MCP-1 in the group
of patients with clinically significant depression (n = 146) was 2.02 ng/ml, while
in the group of patients with subclinical depression (n = 116), it was 0.66 ng/ml
(p < 0.05).
After a correlation analysis, the presence of a statistically significant direct linear
association between the severity of depression and the level of CRP (correlation
coefficient r = 0.85, p < 0.05) as well as between the severity of depression and the
level of MCP-1 (r = 0.8, p < 0.05) was shown.
It was revealed that elevated values of peripheral markers of endothelial inflam-
mation are associated with clinically significant depression. The results are
presented in Table 2. A reliable association was determined between inflammation
and depression (p < 0.001), which remained significant after adjusting for risk
factors for CVD.
Table 1.
Baseline clinical characteristics of patients.
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After 12 weeks of treatment with Divaza, we observed a statistically significant
change in the values of peripheral inflammatory markers toward the reference
values: before treatment, the mean CRP value was 9.25  3.5 mg/l, and after
treatment it was 7.73  3.12 mg/l (p < 0.01); before treatment the average value of
MCP-1 was 2.81  1.3 ng/ml, and after treatment it became 1.9  1.2 ng/ml (p
< 0.01).
Depending on the individual dynamics of peripheral inflammatory marker
values, all patients (n = 262) were divided into two groups: with positive (n = 176)
and with negative (n = 45) dynamics. The values of peripheral markers of endothe-
lial inflammation in the groups before and after treatment are presented in Table 3.
Normalization of peripheral inflammatory and endothelial dysfunction markers
led to psycho-emotional status improvement in patients (Table 4).
The results show that the reduction of inflammation was accompanied by a
decrease in the severity of depressive symptoms, which, in turn, confirms the
association between inflammation and depression.
Table 2.
Association between peripheral markers of endothelial inflammation and depression#.
Table 3.
Peripheral markers of endothelial inflammation level before and after treatment with Divaza.
Table 4.
The severity of depression before and after Divaza treatment.
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To assess the possible involvement of other endothelial mediators in the devel-
opment of depression in patients with cerebral microangiopathy, an integrative
endothelial dysfunction index was calculated.
In factor analysis the most significant variables involved in the formation of
the integrative endothelial dysfunction index were identified. The levels of laboratory
markers of ED with evidence or possible role in the development of endothelial
dysfunction, CRP, MCP-1, VEGF, fibrinogen, Willebrand factor, S100 protein, CECs,
eNOS activity, and endothelin-1, were considered as variables.
CRP, MCP-1, endothelin-1, CECs, and fibrinogen levels statistically significantly
formed one active factor—the integrative endothelial dysfunction index.
Using group of patients who had all laboratory values of ED within the reference
range (n = 41), we defined an average value of the integrative endothelial dysfunc-
tion index equal to 1.32  0.38 conv. units as the age norm.
Comparative analysis of the integrative endothelial dysfunction index values
revealed its statistically significant increase in the group of patients with clinically
significant depression (0.12  0.04 conv. units) compared with the group of
patients with subclinical depression (1.14  0.3 conv. units) (p < 0.05).
A correlation analysis identified the presence of an inverse statistically signifi-
cant correlation between the integrative endothelial dysfunction index and severity
of depression (r = 0.83; p < 0.05).
When evaluating associations, we found that the integrative endothelial dys-
function index is associated with clinically significant depression (OR 1.36, 95% CI
1.23–1.45). The data are presented in Table 5.
The main hypothesis of this study was that in middle-aged patients with cerebral
microangiopathy, the presence of depression is associated with modified levels of
both peripheral inflammatory and endothelial dysfunction markers. To the best of
our knowledge, patients with clinically significant depression were more likely to
have elevated values of peripheral markers associated with endothelial inflamma-
tion and modified levels of ED markers compared with patients with subclinical
depression (p < 0.05).
When studying the correlation between the severity of depression and elevated
values of peripheral markers of inflammation, as well as altered levels of markers of
ED, a significant correlation was found; furthermore there were no association with
age, obesity, and diabetes mellitus (p < 0.001).
The concomitant administration of drugs aimed to correcting the main risk
factors of CVD with Divaza helped to normalize the levels of peripheral inflamma-
tory markers (p < 0.05), which was accompanied by the reduction of depressive
symptoms in middle-aged patients with cerebral microangiopathy.
Table 5.
Integrative endothelial dysfunction index#.
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The study revealed the association between abnormal levels of peripheral
markers of inflammation, markers of ED, and the severity of depression in middle-
aged patients with cerebral microangiopathy accompanied by arterial hypertension
and cerebral atherosclerosis. Drug therapy of endothelial dysfunction contributed to
the normalization of the emotional status in these patients.
Inflammation can be considered as a causative agent of the development of
depression, which is associated with the brain vascular network damage. Damage
of the endothelium stimulates the release of pro-inflammatory cytokines, which
play a leading role in the deposition of lipids in the arterial wall and proliferation
and migration of smooth myocytes into the intima of the blood vessels, causing
thrombus formation followed by occlusion of the blood vessels.
Previous studies showed that patients with severe types of depression had
elevated levels of peripheral inflammatory markers compared with patients without
depression [54]. In particular, a major depressive disorder is accompanied by the
dysregulation of the immune system with activation of the factors participating in
the inflammatory response [55]. An increase in the secretion of pro-inflammatory
cytokines (IL-1β, IL-2, IL-6, Interferon-gamma, TNF-α, etc.) and CRP has been
demonstrated [56]. Our results further indicate the dependence of the level of
depression on the levels of inflammatory markers.
As a possible mechanism of the association between peripheral inflammatory
markers and depression, the involvement of microglia, which is able to use pro-
inflammatory cytokines as catalysts for tryptophan degradation, was considered.
Alteration of tryptophan metabolism can cause depressive symptoms by reducing
serotonin synthesis [57].
IL-6 is a potent stimulator of the hypothalamic-pituitary-adrenal axis and
induces the release of other pro-inflammatory cytokines [58]. These observations
led Leonard B.E. to the conclusion that depression is a disease of inflammation in
response to chronic psychological stress. The author considered stress as a common
denominator in the etiopathology of cerebrovascular diseases, cardiovascular
diseases, and depression [59].
CRP is a protein of the acute phase of inflammation that is activated by pro-
inflammatory cytokines (e.g., IL-6) [60]. CRP is usually studied in the context of
vascular medicine; however, elevated CRP levels are a risk factor for atherosclerosis
and cardiovascular diseases. Therefore, the relationship between CRP and cardio-
vascular diseases was beyond the scope of cardiology. In recent decades, CRP has
become a central element for psychiatric research, especially in the area of depres-
sion. Depressed patients have been shown to exhibit significantly higher levels of
CRP compared to patients in the control group [61].
Wium-Andersen et al. demonstrated an association between CRP levels and
psychological stress in 73,131 Copenhagen residents. After adjusting for age, gender,
smoking, physical activity, and chronic somatic diseases, it was noted that elevated
levels of CRP correlated with depression [62].
The meta-analysis performed by Howren et al. summarizes data from studies on
participants with elevated level of inflammatory markers (CRP, IL-1, IL-6) and
depression, taking into account the BMI. Researchers concluded that there are
associations between high CRP level and depression after adjusting for BMI [63].
This suggests that the relationship between CRP and depressive disorders does not
depend on BMI. In our study, similar results were obtained: an association was
found between the level of CRP and depression—OR 4.17 (95% CI 1.18–14.7,
p < 0.001), which persisted after adjustment for age, obesity, and diabetes mellitus
—OR 1.5 (95% CI 1.3–1.8, p < 0.001). These facts demonstrate the independent
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character of the mutual effects between the activity of the inflammatory processes
and the level of depression.
Despite this, many hypotheses have been proposed regarding the association of
elevated CRP values with depression using various covariates that can affect these
relationships: from BMI and general physical health to the type of depression, which
makes it likely that there is a multifactorial and bi-directional relationship between
depression and inflammation [64].
Frasure-Smith et al. demonstrated that the association between CRP level and
depression is important for predicting future adverse cardiovascular events [65].
There is a lot of evidence in the scientific literature about significant and sustained
elevations of CRP level in depressed patients, which may or may not normalize after
remission of depression symptoms, indicating a continued possibility of adverse
cardiovascular events even after recovery from depression [66].
In 2015, the results of Setiawan E. et al. were published, where authors con-
cluded that depression causes inflammation. The researchers obtained the first
nonexperimental evidence that besides neurons, glial cells, namely, microglia, play
an important role in depressive disorders [67]. However, despite these findings, it is
difficult to conclude that depressive disorders are a trigger of inflammation. It is
possible that stress and other risk factors lead to depressive disorders that affect the
activation of microglia and a change in its structure, in turn, increasing the level of
depression, i.e., it may be a continuum. The data obtained in the present study on
the reduction of the level of depression (p < 0.05) accompanied by a decrease in the
inflammatory activity of the endothelium with the help of a therapy that does not
have an antidepressant effect also suggest the two-sided associations between
inflammation and depression.
ED is a vascular phenotype that predisposes to atheromatosis and atherosclerosis
and, therefore, may be a predictor of cardiovascular events [68].
Endothelial dysfunction can lead to immunological changes, activation, adhesion
of white blood cells, and aggregation of platelets in the vascular damage area. The
attachment of monocytes and lymphocytes to endothelial cells is associated with the
activation of cell adhesion molecules [69]. Chronic mild inflammation is known as a
predictor of myocardial infarction and ischemic stroke. ED is a “critical intermedi-
ate phenotype” in the association between mild inflammation and CVD. ED can be
considered as an “intermediate phenotype” in depression based on the presence of
mild chronic inflammation in many patients with depressive symptoms [70].
Depression can be regarded as a chronic stressor that contributes to the develop-
ment of ED due to the disruption of cell adhesion, platelet hypercoagulation.
Depression is associated with higher levels of MCP-1, p-selectin, and others. Some
researchers consider ED as a biomarker of arterial atheromatosis, which can be a
sign of depression [71]. The present study has shown that there are strong associa-
tions between inflammatory markers and markers of proatherogenic activity
(endothelin-1, CECs, and fibrinogen). Based on the values of CRP, MCP-1,
endothelin-1, CECs, and fibrinogen, an integrative indicator of endothelial dys-
function had higher values in patients with clinically significant depression, com-
pared with patients with subclinical depression (p < 0.01). An inverse statistically
significant correlation was found between the integrative endothelial dysfunction
index and severity of depression (r = 0.83; p < 0.05). Moreover, this association
between the integrative endothelial dysfunction index and depression did not
depend on age, type 2 diabetes mellitus, and obesity (p < 0.001)—the risk factors
known to raise the incidence of CVD.
Do et al. focused on the association of individual symptoms of depression
(a symptom of hopelessness that can turn into suicidality) with markers of ED.
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The researchers concluded that negative psychosocial features which can affect
cardiovascular diseases in part through their impact on the early stages of athero-
sclerosis, as well as specific psychosocial features such as hopelessness, may play a
more significant role in this process than other depressive symptoms [72].
Thus, ED is a crucial factor in the bilateral relationship between depression,
chronic inflammation, and cardiovascular diseases [73].
3. Conclusions
Despite growing evidence that underlines the bilateral relationship between
depression and CVD and the fact that the mechanisms of their connection were
partially identified (e.g., inflammation, ED), further research with a large sample
size is required.
Novel pharmacological approaches based on discoveries related to the immune
and neurotransmitter systems are in high demand.
The development and implementation of preventive measures and lifestyle cor-
rection, which can reduce the burden of cerebrovascular diseases and depression,
are required as well.
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Appendix
Drug Studied activity Test system Results Ref
Pharmacodynamics
RAF of
Abs to
S100
Neuroprotective
activity
Mouse neuroblastoma
C-1300 cells deprived
of glucose and O2
RAF of Abs to S100 added to
the incubation medium
accurately before or 20 h
before the hypoxia induction
increased the number of
survived cells by 1.8- and 2.1-
times, respectively
[33]
Antidepressive activity Adult outbred male
albino rats
RAF of Abs to S100 increased
the number of the wheel turns
in Nomura forced swimming
test by 1.8-2.2-times
[34, 35, 36]
RAF of Abs to S100 decreased
the duration of immobility in
Porsolt forced swimming test
by 1.6-times
[35]
Anxiolytic activity Adult outbred male
albino rats
RAF of Abs to S100 increased
the number of punished water
intakes in Vogel conflict test by
1.4-3.2-times
[34, 36, 37,
38, 39]
RAF of Abs to S100 increased
the number of entries into open
arms of EPM, the time spent in
open arms and the number of
leanings over the edge of the
maze by 1.9-, 5.4- and 4.9-
times, respectively
[34, 39]
RAF of Abs to S100 increased
the number of entries into the
center of the open field up to
2.40.7 vs 00 in control
group
[34, 39]
Adult Rj:Wistar
(Han) male rats
RAF of Abs to S100 increased
the number of punished water
intakes in Vogel conflict test by
1.5-times
[38]
RAF of
Abs to
eNOS
Endothelio-protective
activity
Adult Wistar male
rats with NO
deficiency, induced
by L-NAME
RAF of Abs to eNOS reduced
arterial blood pressure
(184.37.0 mm Hg vs
190.36.7 mm Hg in L-NAME-
group) and the exhaustion of
myocardial fractional flow
reserve by 11%
[40]
Adult Wistar male
rats with NO
deficiency, induced
by L-NAME
RAF of Abs to eNOS improved
microcirculation in the
ischemic area, stimulated
neoangiogenesis and promoted
recruitment of additional
capillaries into general
circulation;
RAF of Abs to eNOS improved
the metabolism of endothelial
capillaries and significantly
[41]
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Drug Studied activity Test system Results Ref
decreased the number of
desquamated endotheliocytes
that was the unique
morphological criteria for
endothelium damage degree
Adult Wistar male
rats with
hypoestrogen-
induced NO
deficiency
RAF of Abs to eNOS reduced
arterial blood pressure
(158.515.0 mm Hg vs
160.06.2 mm Hg in control
group) and the exhaustion of
myocardial fractional flow
reserve by 26.9%
[40]
Antidepressive activity Adult outbred male
rats
RAF of Abs to eNOS increased
the number of punished water
intakes in Vogel conflict test by
1.6-times
[42]
Anxiolytic activity Adult outbred male
rats
RAF of Abs to eNOS increased
the number of entries into open
arms of EPM and time spent in
open arms up to 1.500.71 and
34.4 8.50 s (vs 00 in control
group for both parameters),
respectively
[42]
Influence on the
cardiovascular system
Hypertensive adult
ISIAH male rats
RAF of Abs to eNOS reduced
arterial blood pressure by 5.7%
[43]
Normotensive adult
Wistar male rats
RAF of Abs to eNOS did not
affect systemic hemodynamics,
did not augment nitroglycerine
effects
[44]
Divaza Endothelio-protective
activity
Thoracic aorta rings
of adult male SHR
rats
Divaza improved
acetylcholine-induced
relaxation of aorta vascular
smooth muscle by 1.4-times
Un-
published
data
Neuroprotective
(antioxidant) activity
Adult outbred male
rats with
experimental acute
hemic hypoxia
Divaza decreased the content
of diene conjugates in the
cerebral hemispheres by 9.7-
27.8% in the heptane fraction
and by 7.5-47.4% in
isopropanol fraction. The
accumulation of 2-
thiobarbituric acid-reactive
products was reduced by 20.1-
27.5%
[45]
Neurotropic activity
(neurite outgrowth)
Brain cortex neurites
of rat fetuses
(gestational day 17)
without any
branching
Divaza increased the value of
neurite outgrowth by 9.6%
Un-
published
data
Anti-amnestic activity Adult Wistar male
rats with β-amyloid-
induced amnesia
Divaza increased the latency of
the entry into the dark
compartment of CPAR
experimental chamber by 3-
times
[46]
Antidepressive activity Adult outbred male
rats
Divaza increased the number
of the wheel turns in Nomura
[47]
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Drug Studied activity Test system Results Ref
forced swimming test by 1.8-
times
Anxiolytic activity Adult outbred male
rats
Divaza increased the number
of punished water intakes in
Vogel conflict test by 2.5-times
[47]
Mechanisms of action
RAF of
Abs to
S100
Influence on Abs to
S100 activity (ability to
induce LTP)
Hippocampal slices
(400 μm) of mature
Wistar rats
Abs to S100 inhibited the
induction of LPT, whereas RAF
of Abs to S100 offset this
inhibiting activity
[48]
Influence on electrical
properties of cell
membranes
Isolated neurons of
Helix pomatia
RAF of Abs to S100 suppressed
generation of action potential
in a dose-dependent manner
and increased the maximal
speed of its growth via
changing the volt-ampere
characteristics of the incoming
current channels
[49]
Involvement of
GABAA-ergic system in
the realization of RAF
of Abs to S100 effects
Adult outbred male
albino rats
Bicuculline and picrotoxin
(GABAA-receptors
antagonists) decreased the
anxiolytic effect of RAF of Abs
to S100 in Vogel conflict test
by 1.8- and 1.6-times,
respectively
[37]
Involvement of
GABAB-ergic system in
the realization of RAF
of Abs to S100 effects
Adult outbred male
rats
Baclofen (GABAB-receptors
agonist) decreased the
anxiolytic effect of RAF of Abs
to S100 in Vogel conflict test
by 2.2-times, whereas
phaclofen (GABAB-receptors
antagonist) increased it by 1.4-
times; both baclofen and
phaclofen decreased
antidepressive effect of RAF of
Abs to S100 in Nomura’s forced
swimming test by 1.5- and 1.7-
times, respectively
[50]
CHO cells expressing
human GABA
receptors
RAF of Abs to S100 exerted
antagonism at GABAB1A/B2-
receptors inhibiting agonist-
induced responses by 30.2%
and also inhibited specific
binding of ([3,4-3H]-
cyclohexylmethyl)phosphinic
acid ([3H]-CGP54626) to
GABAB1A/B2-receptors by
25.8%
[51]
Involvement of
serotonergic system in
the realization of RAF
of Abs to S100 effects
Adult outbred male
rats
Ketanserin (5-НТ2 receptors
antagonist) decreased both the
anxiolytic effect of RAF of Abs
to S100 in Vogel conflict test
and antidepressive effect of
RAF of Abs to S100 in Nomura
forced swimming test by 1.9-
and 2-times, respectively
[36]
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Drug Studied activity Test system Results Ref
CHO and CHO-K1
cells
RAF of Abs to S100 increased
specific radioligands binding to
5-HT1F-, 5-HT2B-, 5-
HT2Cedied- and 5-HT3-
receptors by 142.0%, 131.9%,
149.3% and 120.7%,
respectively; also RAF of Abs to
S100 exerted antagonist effect
at 5-HT1B-receptors inhibiting
their functional activity by
23.2% and agonist effect at 5-
HT1A-receptors enhancing
their functional activity by
28.0%
[51]
Involvement of
dopaminergic system in
the realization of RAF
of Abs to S100 effects
CHO and CHO-K1
cells
RAF of Abs to S100 increased
specific radioligand binding to
D3-receptors by 126.3% and
exerted antagonism at D3-
receptors inhibiting their
functional activity by 32.8%
[51]
Involvement of
glutamatergic system in
the realization of RAF
of Abs to S100 effects
Rat brain cortex
neuronal cells
RAF of Abs to S100 decreased
specific radioligand binding to
NMDA-receptors by 39.1%
[52]
Involvement of σ1-
receptor in the
realization of RAF of
Abs to S100 effects
Human leukemic Т-
cell line (Jurkat);
human breast cancer
cell line (MCF-7)
RAF of Abs to S100 decreased
specific radioligand binding to
native and recombinant human
σ1-receptors by 75.3% and
40.3%, respectively
[51]
RAF of
Abs to
eNOS
Effects on vascular
endothelial function
Cavernous bodies of
adult Wistar male rats
RAF of Abs to eNOS increased
eNOS activity, the content of
NO derivates and the content
of cGMP by 2.4-, 1.3- and 4-
times, respectively
[53]
Divaza Involvement of σ1-
receptor in the
realization of Divaza
effects
Segments of vas
deferens of male
albino Dunkin-
Hartley guinea-pigs
Divaza increased the amplitude
of tissue contraction induced
by standard agonist by 2-times
[54]
Notes: * - adapted from [73], CPAR - conditioned passive avoidance reflex, EPM - elevated plus maze, LPT - long-
term potentiation.
Appendix 1.
Experimental studies of pharmacological activity and mechanisms of action of RAF of Abs to S100, RAF of Abs
to eNOS and combination drug Divaza.
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